Evidence map›Paper›PMID 41959408›Full record

ArticlebioRxiv : the preprint server for biology2026

Intranasal immunization with live-attenuated RSV-vectored SARS-CoV-2 vaccines elicits antigen-specific systemic and mucosal immunity and protects against viral challenge and natural infection.

Davide Botta, Michael D Schultz, Aaron Silva-Sanchez, Davies Kalange, Jobaida Akther, Fen Zhou, Jennifer L Tipper, Guang Yang, Levi T Schaefers, Courtney A Barkley and 13 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Davide BottaDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-3926-0662
Michael D SchultzDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-6741-4115
Aaron Silva-SanchezDepartment of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-1882-2534
Davies KalangeDepartment of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0009-0006-6337-1599
Jobaida AktherDepartment of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-3096-3663
Fen ZhouDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0009-0008-9174-123X
Jennifer L TipperDepartment of Anesthesiology and Perioperative Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Guang YangDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.
Levi T SchaefersDepartment of Pathology, Division of Laboratory Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-0822-0257
Courtney A BarkleyDepartment of Anesthesiology and Perioperative Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Shihong QiuDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.
Jeremy B FooteDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-6621-6096
Mariana F TioniMeissa Vaccines Inc, Redwood City, CA, USA.ORCID 0000-0002-7865-3023
Christopher M WeissMeissa Vaccines Inc, Redwood City, CA, USA.ORCID 0000-0003-4704-9533
Shannon I PhanMeissa Vaccines Inc, Redwood City, CA, USA.
Todd J GreenDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.
Sixto M LealDepartment of Pathology, Division of Laboratory Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-6939-9572
Kevin S HarrodDepartment of Anesthesiology and Perioperative Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-0780-9470
Rodney G KingDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-6522-0053
Martin L MooreMeissa Vaccines Inc, Redwood City, CA, USA.
Troy D RandallImmunology Institute, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-0643-0311
Roderick S TangMeissa Vaccines Inc, Redwood City, CA, USA.ORCID 0000-0003-0018-4869
Frances E LundDepartment of Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-3083-1246

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Construction/SEBLAB/Regional Biocontainment LaboratoryUC6AI058599 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MARCHASE, RICHARD BANFIELD · 2003 to 2006
$22.0M
Tissue and organ specific human B cell immunity: Supplement - Metabolic Risk Factors and Inflammation in PASC DevelopmentU19AI142737 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TECTOR, A JOSEPH · 2019 to 2023
$19.7M
Facility Management, Maintenance and Operations CoreUC7AI180255 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Sixto Manuel Leal · 2023 to 2026
$13.3M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Upgrade and operational improvements to the SouthEastern Biosafety Laboratory, Alabama, Birmingham (SEBLAB)G20AI167409 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEAL, SIXTO MANUEL · 2021 to 2022
$7.7M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
NCI NIH HHS P30 CA013148NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS G20 AI167409NIAID NIH HHS P30 AI027767NIAID NIH HHS U19 AI142737NIAID NIH HHS UC6 AI058599NIAID NIH HHS UC7 AI180255NIDA NIH HHS 75N95020D00005NIH HHS 75N93023D00005NIH HHS 75N99020D00005
6 · The paper itself

Abstract

The emergence of new SARS-CoV-2 variants and breakthrough infections underscores the need for next-generation vaccines capable of protecting from natural infection and/or preventing virus transmission to others. Intranasal vaccination offers a promising approach by eliciting local immune responses in the nasal mucosa, the primary site of infection and reservoir for transmissible virus. We evaluated two live-attenuated, respiratory syncytial virus vectored vaccines in which the RSV F and G surface glycoproteins were replaced with a chimeric SARS-CoV-2 Spike protein from either the ancestral USA/WA-1/2020 strain (MV-014-212) or the Delta variant (MV-014-212-delta). A single intranasal dose of either vaccine elicited systemic and mucosal immunity in K18-hACE2 mice, including serum neutralizing antibodies, Spike-specific memory B cells and plasmablasts, and Spike-specific CD8

Identifiers

PMID41959408
PMCPMC13060200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.